Murine Chemokine CXCL2/KC Is a Surrogate Marker for Angiogenic Activity in the Inflammatory Granulation Tissue
- 11 October 2005
- journal article
- Published by Wiley in Microcirculation
- Vol. 12 (7), 597-606
- https://doi.org/10.1080/10739680500253535
Abstract
Objectives: A wide range of compounds inhibit formation of new blood vessels in a variety of models, accompanied by decreases in pro‐angiogenic cytokines. The authors sought a surrogate marker for the complex process of neovascularization by correlating inhibition of cytokine production with anti‐angiogenic effect. Methods: Three anti‐angiogenic compounds, clotrimazole (120 mg kg−1 day−1), thalidomide (100 mg kg−1 day−1), and rosiglitazone (10 mg kg−1 day−1), were used to inhibit angiogenesis developing over 9 days, in sponges implanted subcutaneously in Swiss mice. Angiogenesis was assessed by hemoglobin content and by histology. Content of cytokines in implants was measured by specific immunoassays and accumulation of neutrophils or macrophages in implants by measuring myeloperoxidase or N‐acetylglucosaminidase activity, respectively. Results: These compounds caused equal inhibition of angiogenesis (about 40%). However, implant levels of vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF‐α) or the macrophage chemoattractant cytokine, CCL2/MCP‐1/JE, and accumulation of macrophages were more variably inhibited. Only the neutrophil chemokine, CXCL2/KC, was inhibited equally by the three compounds, in this model. Conclusions: Anti‐angiogenic effect was most clearly and closely correlated with levels of the chemokine KC. Thus, measurement of the chemokine KC might provide an adequate surrogate marker for the functional process of neovascularization in our model.Keywords
This publication has 29 references indexed in Scilit:
- Blockade of Keratinocyte-Derived Chemokine Inhibits Endothelial Recovery and Enhances Plaque Formation After Arterial Injury in ApoE-Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Regulation of neovascularization by human neutrophil peptides (α‐defensins): a link between inflammation and angiogenesisThe FASEB Journal, 2004
- Sponge-induced angiogenesis and inflammation in PAF receptor-deficient mice (PAFR-KO)British Journal of Pharmacology, 2004
- Inhibitory effect of troglitazone on TNF-α-induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cellsDiabetes Research and Clinical Practice, 2000
- Peroxisome Proliferator-activated Receptor γ Ligands Are Potent Inhibitors of Angiogenesis in Vitro and in VivoJournal of Biological Chemistry, 1999
- Suppression of VEGF‐induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin ABritish Journal of Pharmacology, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.The Journal of Experimental Medicine, 1991
- Neutrophil-activating properties of the melanoma growth-stimulatory activity.The Journal of Experimental Medicine, 1990
- Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line.The Journal of Experimental Medicine, 1989